Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

9.160 +0.170 (+1.89%)
Streaming Delayed Price Updated: 1:13 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 621,466
Open 8.990
Bid (Size) 9.150 (100)
Ask (Size) 9.170 (200)
Prev. Close 8.990
Today's Range 8.710 - 9.200
52wk Range 1.780 - 13.67
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill

Performance

YTD
+133.7%
+133.7%
1 Month
+24.0%
+24.0%
3 Month
+44.3%
+44.3%
6 Month
+164.0%
+164.0%
1 Year
+130.2%
+130.2%

More News

Read More
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
Via AB Newswire
News headline image
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Which stocks are gapping on Monday? ↗
Via Chartmill
News headline image
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome? ↗
Via Stocktwits
News headline image
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
Via Benzinga
News headline image
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?
Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?
The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market
What is the current price of Kyverna Therapeutics, Inc. - Common Stock?
The current price of Kyverna Therapeutics, Inc. - Common Stock is 9.160
When was Kyverna Therapeutics, Inc. - Common Stock last traded?
The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 12/26/25 01:13 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.